Movatterモバイル変換


[0]ホーム

URL:


CN1548529A - A method for isolating human placental mesenchymal stem cells - Google Patents

A method for isolating human placental mesenchymal stem cells
Download PDF

Info

Publication number
CN1548529A
CN1548529ACNA031235042ACN03123504ACN1548529ACN 1548529 ACN1548529 ACN 1548529ACN A031235042 ACNA031235042 ACN A031235042ACN 03123504 ACN03123504 ACN 03123504ACN 1548529 ACN1548529 ACN 1548529A
Authority
CN
China
Prior art keywords
cell
placenta
msc
stem cells
mesenchymal stem
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA031235042A
Other languages
Chinese (zh)
Inventor
毅 张
张毅
李长东
江小霞
何津
刘元林
张双喜
吴英
毛宁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Basic Medical Sciences of AMMS
Original Assignee
Institute of Basic Medical Sciences of AMMS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Basic Medical Sciences of AMMSfiledCriticalInstitute of Basic Medical Sciences of AMMS
Priority to CNA031235042ApriorityCriticalpatent/CN1548529A/en
Publication of CN1548529ApublicationCriticalpatent/CN1548529A/en
Pendinglegal-statusCriticalCurrent

Links

Images

Landscapes

Abstract

Translated fromChinese

本发明公开了一种人胎盘间充质干细胞的分离方法。本发明的发明人在总结以往分离组织细胞的基础上,利用胎盘特殊的解剖结构,采用灌流法,成功自胎盘中分离获得纯度较高的MSC。鉴定结果表明从胎盘中分离的间充质干细胞与以往报道的骨髓间充质干细胞具有相同的生物学特性和多向分化能力。由于胎盘与脐血一样,细胞成分较幼稚,来源广泛,方便易得,因此在临床上将具有广泛的应用前景。

Figure 03123504

The invention discloses a method for separating human placenta mesenchymal stem cells. The inventors of the present invention, on the basis of summarizing the previous isolation of tissue cells, took advantage of the special anatomical structure of the placenta and adopted the perfusion method to successfully separate and obtain MSCs with high purity from the placenta. The identification results showed that the mesenchymal stem cells isolated from the placenta had the same biological characteristics and multilineage differentiation ability as the previously reported bone marrow mesenchymal stem cells. Because the placenta, like cord blood, has immature cell components, a wide range of sources, and is convenient and easy to obtain, it will have broad application prospects in clinical practice.

Figure 03123504

Description

A kind of separation method of people's placenta mesenchyma stem cell
Technical field
The present invention relates to a kind of separation method of cell, relate in particular to a kind of separation method of people's placenta mesenchyma stem cell.
Background technology
Human mesenchymal stem cell (mesenchymal stem cell, MSC) be the tissue stem cell that an isolated class has multidirectional differentiation potential and self ability in marrow the earliest, derive from the mesoderm of embryo's emergence period, in vivo with external specified conditions under can be to scleroblast, the chondrocyte, adipocyte, the myocyte, Tenocyte cell, liver cell even neurogliocyte differentiation (1.Caplan AI.Mesenchymalstem cells.J Orthop Res.1991,9:641-650.2.Pittenger MF, Mackay AM, Beck SC, et al.Multilineage potential of adult human mesenchymal stem cells.Science.1999; 284:143-147.).MSC is easy to separation and purification from marrow, carry out effective amplification in vitro, its biological action result of study is shown, MSC has the bone marrow microenvironment of improvement, promote hematopoiesis to transplant effect (the 1.Kadereit S of back hematopoietic reconstitution, Deeds LS, Haynesworth S, et al.Expansion ofLTC-ICs and Maintenance of p21 and BCL-2 Expression in Cord BloodCD34+/CD38-Early Progenitors Cultured over Human MSCs as a Feeder Layer.Stem cell.2002; 20:573-582.2.Koc ON, Gerson SL, Cooper BW, et al.Rapidhematopoietic recovery after coinfusion of autologous-blood stem cells andculture-expanded marrow mesenchymal stem cells in advanced breast cancerpatients receiving high-dose chemotherapy.J Clin Oncol.2000; 18:307-316.3.Klyushnenlova E, Mosca J, McIntosh K.Human mesenchymal stem cells suppressallogeneic T cell responses in vitro:implications for allogeneic transplantation.Blood.1998; 92:642a.).The immunological characteristic aspect, MSC does not express or only expresses the MHC II quasi-molecule that can ignore level, the MSC of uncorrelated donor does not cause the allosome lymphocyte reaction, can reduce allosome immune response (1.McIntosh K, Klyushnenkova E, Shustova V, et al.Suppression ofalloreactive T cell reaponse by human mesenchymal stem cells involves CD8+cells.Blood.1999; 94:133a.2.Klyushnenkova E, Shustova V, Mosca J, et al.Human mesenchymal stem cells induce unresponsiveness in preactivated but notnative alloantigen specific T cells.EXP Hematol.1999; 27:122.).Based on above-mentioned feature, make it after finding, become the desirable engineering cell that cell therapy, gene therapy, effectively plays a role rapidly, and organizational project important seed cell in bone or the cartilaginous tissue injury repairing especially.
The MSC that is reported at present is mainly derived from marrow, adopts density gradient centrifugation to obtain.Though separation method is easy, donor is got marrow need experience a relatively more painful operation, and has very high infection chance in the process of drawing materials and after drawing materials; Because the content of MSC is extremely rare among the human bone marrow, per 105~106Approximately has only 1 in the individual mononuclearcell, and increase along with the age, the quantity of MSC, propagation and differentiation capability all significantly descend (Rao MS, Mattson MP.Stem cells and aging:expanding the possibilities.Mech Ageing Dev.2001 in the marrow; 122:713-734.), make it in research with use in the especially clinical application and be restricted.
Recently, existing mesenchymal cell with stem/progenitor cells characteristic is separated (1.Ralf H.Isolation of Primary and Immortalized CD34-Hematopoietic and Mesenchymal Stem Cells from Various Sources.StemCells.2000 from comprising in the tissues such as bone, cartilage, muscle, tendon; 18:1-9.2.Deans RJ, Moseley AB.Mesenchymal stem cells:biology andpotential clinical uses.Exp Hematol.2000; 28:875-884.), it is exactly the mesoderm that derives from embryonic development period that these tissues have a common feature.
Originate from the placenta of embryonic development period extraembryonic mesoderm and form, contain a large amount of mesenchyme compositions by a matter, blood vessel and nurse cell.In fetal development period, the multipotential stem cell of extraembryonic mesoderm has a spot of not being recruited to be broken up, and be present in the placenta tissue with static form, if can from placenta, separation and Culture go out MSC, will open up a brand-new and abundant source for experimental study and clinical application.U.S.'s hematology annual meeting in 2000, report such as Jaroscak adopts enzyme digestion, placenta tissue is shredded with surgical scissors, after adding histaminase digestion certain hour, filter and obtain cell suspension, be inoculated in the substratum, after cultivating after a while, in the visible culturing bottle attached cell is arranged, continue to cultivate, the placenta attached cell that obtains is adopted the Flow cytometry cell surface marker, the result shows placenta attached cell and marrow MSC not obviously difference on the cell surface marker dyeing property of acquisition, but the placenta attached cell is heterogeneous, cell surface marker SH2, SH3, SH4 etc. are positive; Do not express CD45, PECAM, pointing out it is non-hematopoietic cell and endotheliocyte, illustrate and have MSC composition (Jaroscak J in the placenta, Smith T, Haynesworth S, et al.Preliminary characterization of the surface stainingof placental derived adherent cells:A potential new souece of stroma for umbilicolcord blood (UCB) expansion.THE AMERICAN SOCIETY OFHEMATOLOGY, December 1-5,2000.).Employing enzyme digestions such as Japanese scholar Watanabe in 2002 or tissue culture method are isolated MSC in conjunction with the flow cytometry separating method from placenta, concrete grammar is mainly placenta tissue is shredded, histaminase digestion or directly tissue block cultivation, the required cell of selected by flow cytometry apoptosis, after continuing to cultivate for some time, carry out cytobiology and identify that also inducing cell is to becoming fat, skeletonization with become cartilage differentiation, further inducing cell neuralward cytodifferentiation (Watanabe N, Igura K, Nagamura-Inoue T, et al.Multilineage potential of human placenta-derivedmesenchymal cells.THE AMERICAN SOCIETY OF HEMATOLOGY, December 1-5,2002).But separation method recited above is all comparatively loaded down with trivial details.
Summary of the invention
The objective of the invention is to disclose a kind of method of easy separation of human placenta mesenchyma stem cell (MSC), this method may further comprise the steps:
According to the anatomical structure of placenta, under aseptic condition, insert conduit from umbilical blood vessels and form the circulating liquid perfusion system.With the DMEM that contains heparin or IMDM substratum as perfusate.Residual blood is washed out by the arteriovenous circulation with perfusate earlier, hatch with perfusate then.Adopt density gradient centrifugation to separate mononuclearcell from perfusate, cultivate with the MSC substratum suspension cell that obtains the washing back.After treating that disseminated cell forms the clone, each clone cell chosen with the MSC substratum cultivate respectively, after cell 80~90% merges, go down to posterity with trysinization, the cell that reaches more than 3 generations is frozen in liquid nitrogen, and carry out the biological characteristics and the evaluation of multidirectional differentiation potential of cell.
The biological characteristics of cell is identified and has been carried out cell growth characteristic and the evaluation of morphology characteristics, flow cytometry identification of M SC surface marker, the analysis of placenta MSC cell cycle, the drafting of placenta MSC growth curve and the mensuration of logarithmic phase doubling time.
The multidirectional differentiation potential of placenta MSC identify carried out that one-tenth fat is induced, osteogenic induction with become chondrocyte induction.
The experimental result explanation, isolating attached cell has identical biological characteristics and multidirectional differentiation capability with the mesenchymal stem cells MSCs of reporting in the past from placenta, i.e. successfully separation from people's placenta, purifying, acquisition mescenchymal stem cell.
MSC mainly adopts modus operandi to extract donor marrow at present, and density gradient centrifugation is separated mononuclearcell, is inoculated in to cultivate in the MSC special culture media to obtain.This method complex operation, donor is being got the possibility that infection is all arranged after marrow is got in the marrow neutralization.The contriver utilizes the special anatomical structure of placenta summing up on the basis of chorista cell in the past, adopts perfusion method, and success separates in placenta and obtains the higher MSC of purity.
This method is simple and easy to do, and because placenta is the same with bleeding of the umbilicus, the cell composition is inmature, and wide material sources conveniently are easy to get, and therefore method of the present invention will be with a wide range of applications clinically.
Description of drawings
Fig. 1 observes under the cell growth morphology mirror.Wherein
A is for cultivating the attached cell that as seen is dispersed in behind the 3d
B is that 7~10d forms the clone
C is for to form fine and close attached cell through screening and cloning
D is the dyeing of Rui Shi Ji's nurse Sa
Fig. 2 is flow cytometry identification of M SC surface marker result.
Fig. 3 is the analytical results of placenta MSC cell cycle.
Wherein P3 is for cultivating the dna content of third generation cell, and in the analysis of cells cycle, visible most of cell is in stationary phase (G0/G1 phase, 96.66%), and few cell is in the propagation phase (S phase, 3.25%).
P6 is for cultivating the dna content of hexabasic cell, and in the analysis of cells cycle, visible most of cell is in stationary phase (G0/G1 phase, 96.35%), and few cell is in the propagation phase (S phase, 2.54%).
Fig. 4 is cell growth curve figure.
Fig. 5 is the one-tenth fat inducing cell figure that the multidirectional differentiation potential of placenta MSC is identified.
Wherein A is for inducing 3d, the cellular control unit form
B is for inducing 3d, and the experimental group cellular form changes
C-D is for inducing 7d, and visible endochylema lactones drips formation
E-F is that oil red dyeing fat drips by specificity and dyes redness
Fig. 6 is the osteogenic induction cytological map that the multidirectional differentiation potential of placenta MSC is identified.
Wherein A is for inducing 1w, the cellular control unit form
B is for inducing 1w, and the experimental group cellular form changes
C is for inducing 2w, and original position dyeing shows the alkaline phosphatase expression of enzymes positive
D is for inducing 2w, and smear staining shows the alkaline phosphatase expression of enzymes positive
E-F is for inducing 4w, and von Kossa dyeing shows that the bone tubercle forms
Fig. 7 is the one-tenth chondrocyte induction cytological map that the multidirectional differentiation potential of placenta MSC is identified.
Wherein A is for inducing 2w, cellular control unit Alcian blue dyeing
B is for inducing 2w, experimental group cell Alcian blue dyeing
C-D is that visible II Collagen Type VI formation extracellular matrix is dyed blueness by specificity under the high power lens
Embodiment
Embodiment one placenta MSC isolation cultivation method
According to the anatomical structure of placenta, under aseptic condition, insert polyethylene catheter from umbilical blood vessels (2 Umbilical artery and 1 umbilical vein) and form the circulating liquid perfusion system, with the DMEM that contains heparin or IMDM substratum as perfusate.Residual blood was washed out in 0.5~2.5h in postpartum by the arteriovenous circulation with perfusate earlier, hatch 12~24h for 20~25 ℃ with 100~250ml perfusate then.Adopt density gradient centrifugation from perfusate, to separate mononuclearcell, wash back with the MSC substratum suspension cell that obtains, 37 ℃, 5%CO2After cultivating 24~48h under the complete wet condition, change liquid and remove not adherent suspension cell, continue to cultivate, change liquid once every 3~4d.After treating that early stage disseminated cell forms the clone, each clone cell chosen with the MSC substratum cultivate respectively, after cell 80~90% fusions, use 0.25% trysinization, went down to posterity in 1: 3 or 1: 4, the cell that reaches more than 3 generations is used for following experiment, and frozen part cell is for future use in liquid nitrogen.
The biological characteristics of embodiment two placenta MSC is identified
One, cell growth characteristic and morphology characteristics
Cultivate by embodiment one method, need 3d approximately, as seen be dispersed under the mirror and be the fusiform attached cell, form radial clone about 7~10d, each clone is chosen respectively to 24 orifice plate single culture.Treat cell purification to 3 after generation, be used for characteristics of cell biology and detect.In the culturing process, find the relative homogeneous of this cellular form, rate of growth is fast, and adherent speed is fast, easily by trysinization, is passaged to more than 15 generations, and its form and growth characteristic also do not have obvious change.See Fig. 1.
Two, flow cytometry identification of M SC surface marker
Get respectively the 3rd, 6,9,12,15 generation cell, the Flow cytometry surface marker dynamic observes the variation of surface marker in the culturing process.The digestion collecting cell gets 5 * 10 behind the counting6Individual, packing 10 pipes; PBS washes once, the centrifugal 10min of 1500rpm; Abandon supernatant, residual 100~200 μ l, piping and druming mixing cell; Add CD29, each 10 μ l of CD44 antibody of CD45, CD105, HLA-DR, UEA-1 antibody and indirect labelling of CD34, CD73, CD166 antibody and the FITC mark of PE mark, and establish a pipe and be blank, a pipe is two anti-contrasts; 4 ℃, lucifuge reaction 30min; PBS washes once, the centrifugal 10min of 1500rpm; Directly the cell of mark is abandoned supernatant, adds 200 μ l PBS piping and druming mixing cell, and 1% Paraformaldehyde 96 of 200 μ l is fixed, put 4 ℃ to be measured, the upflowing cell instrument detects in the 3d.The cell of indirect labelling repeats to go up machine testing after the above-mentioned steps after need resisting reaction with two.
Flow cytometer detects the surface marker of cell, dynamic observe derive from each clone the 3rd, 6,9,12,15 generation cell, do not have obviously and change.Not expressing the hematopoietic cell surface marker is that CD34 (HSPC and the endotheliocyte positive), CD45 (the white corpuscle positive), HLA-DR (MHC-II quasi-molecule) continue feminine gender, CD29 and the CD44 (acceptor of scleroproein and transparency grease hydrochlorate, stroma cell is expressed), CD73 (being SH-3,4), CD105 (being SH-2), CD166 (mesenchymal cell expression) and UEA-1 (surface marker of endotheliocyte) are continuously the positive.After going down to posterity more than 3 generations, the cellular constituent homogeneous, purity is more than 95%.See Fig. 2.
Three, the analysis of placenta MSC cell cycle
When cell grows to the 80-90% fusion, digestion collecting cell about 1 * 106Individual, PBS washes once, and the ethanol of adding 70% is fixed, and 4 ℃ to be measured.During detection, the centrifugal ethanol that goes is washed once with PBS more earlier, adds RNaseI 500u, 37 ℃ of reaction 30min, and PBS washes once, adds propidium iodide (PI, final concentration 50 μ g/ml) 1ml, room temperature lucifuge reaction 20min, last machine testing cell DNA content.
After measured the 3rd generation and the 6th generation cell dna content, cell cycle analysis, G0/G1 phase, S phase and G2M phase proportion are respectively 96.35%, 96.66%, 1.11%, 0.09% and 2.54%, 3.25%.The cell of results suggest vitro culture has typical stem cells hyperplasia characteristics, promptly has only a few cell to be in the active propagation phase (1.11%, 0.09%), and most cell is in quiescent stage (96.35%, 96.66%).See Fig. 3.
Four, the drafting of placenta MSC growth curve and the mensuration of logarithmic phase doubling time
The cell in vegetative period of taking the logarithm, the digestion counting is made cell suspension (2 * 10 with the LG-DMEM substratum of 10%FBS4/ ml), every hole inoculation 0.5ml in 24 orifice plates, 37 ℃, 5%CO2, cultivate under the saturated humidity.Get 3 multiple holes every day, trypan blue dyeing back living cell counting number, calculating mean value is observed 7d continuously.With the incubation time is transverse axis, and cell count is the longitudinal axis, draws cell growth curve.Calculate cell in the doubling time of logarithmic phase with the Patterson formula, i.e. Td=Tlg2/Lg (Nt/No), Td: the doubling time (h), T: cell increases to Nt used time (h), N: cell count by No.
Cytometric result draws cell growth curve by every day, calculates the doubling time.By cell growth curve as can be seen, cell is in exponential phase of growth at 2-4d.According to formula calculate the 5th generation cell be respectively 22.6h in the doubling time of exponential phase of growth.See Fig. 4.
The multidirectional differentiation potential of embodiment three placenta MSC is identified
One, become fat to induce
Above MSC of 3 generations is by 1 * 105/ hole is inoculated in six orifice plates, standard medium is cultivated to use instead behind the 24h and is contained the 10% high sugared DMEM through screening FBS, and addsdexamethasone 1 μ M, INDOMETHACIN 200 μ M, IBMX 0.5mM, Regular Insulin 10 μ g/ml, and every 3d half amount is changed liquid, coinduction 2w, oil red dyeing identifies that fat drips formation.
Containing 10% DMEM-HG through screening FBS, addingdexamethasone 1 μ M, INDOMETHACIN 200 μ M, IBMX 0.5mM, Regular Insulin 10 μ g/ml cultivate 3d, form promptly takes place and changes in cell, is shunk gradually by fusiform inoblast sample to shorten, and 90% above cell becomes cube or polygon; Cultured continuously 7d, there have small fat to ooze under the mirror in the visible cell to be existing, and along with the prolongation of incubation time, fat drips and increases gradually and merge, and when cultivating 2w, as seen merges agglomerating fat and drips and be full of whole cell.The fat that produces in the oil red O stain visible cell is dyed redness by specificity.See Fig. 5.
Two, osteogenic induction
Above MSC of 3 generations is by 1 * 105Six orifice plates are inoculated in/hole, cultivate to use instead behind the 24h with standard medium to contain 10% through the DMEM-HG of screening FBS and add dexamethasone 0.1 μ M, ascorbyl phosphate 50 μ M, β-phospho-glycerol 10mM, and amount was changed liquid, coinduction 2-4 week in per 3 days half.Alkaline phosphatase staining identifies that scleroblast forms, and Von Kossa dyeing identifies that the bone tubercle forms.
Containing 10% DMEM-HG through screening FBS, adding dexamethasone 0.1 μ M, ascorbyl phosphate 50 μ M, β-phospho-glycerol 10mM cultivate 1w, cellular form takes place significantly to change, become polygon by fusiform inoblast sample, be similar to the neuronal cell sample, it is outstanding that the long filament shape appears in the cell periphery, and can extend towards periphery.Continue to cultivate 2w above after, calcified plaque appears in the cell matrix, mineralizer engenders, and begins to form the little junction structure of multilayer, after cultivating 4w, visible obviously calcification tubercle.The 2w alkaline phosphatase staining is strong positive reaction, reaches more than 95%, and the inductive control group is then most of not negative in addition, only is shown as the weak positive less than 5%, shows that cell transforms to scleroblast.Von Kossa dyeing can be dyed black with sedimentary calcium in the bone tubercle, induces the visible a large amount of black bone tubercle of group, tangible three-dimensional arrangement is arranged, and control group does not all have positive reaction at any time.See Fig. 6.
Three, become chondrocyte induction
3 generations above cell, low-speed centrifugal makes cell form micelle in test tube, adds each 6.25 μ g/ml of Regular Insulin, Transferrins,iron complexes, Sodium Selenite in containing the DMEM-HG of 2.5%FBS, BSA1.25 μ g/ml, Sodium.alpha.-ketopropionate 1mM/L, xitix phosphoric acid 37.5 μ g/ml, TGF-β150ng/ml, every 3d half amount is changed liquid, cultured continuously 2w.
After inducing 2w the cell micelle is broken up smear, dye visible II Collagen Type VI of Alcian blue forms extracellular matrix and is blue, and control group does not have indigo plant and dyes.See Fig. 7.

Claims (10)

1, a kind of method of separation of human placenta mesenchyma stem cell may further comprise the steps:
(1) under aseptic condition, inserts conduit from umbilical blood vessels and form the circulating liquid perfusion system;
(2) residual blood is washed out by the arteriovenous circulation with perfusate earlier, hatch with perfusate then;
(3) from perfusate, separate mononuclearcell, cultivate;
(4) go down to posterity with trysinization and identify.
2, method according to claim 1 is characterized in that described perfusate is the substratum that contains antithrombotics.
3, method according to claim 2 is characterized in that described antithrombotics is a heparin.
4, method according to claim 2 is characterized in that described substratum is DMEM or IMDM substratum.
5, method according to claim 1 is characterized in that separating mononuclearcell and adopts centrifugation method to realize from perfusion liquid.
6, method according to claim 5 is characterized in that separating mononuclearcell and adopts the method for density gradient centrifugation to realize from perfusion liquid.
7, method according to claim 1 is characterized in that isolating mononuclearcell is cultivated with the MSC substratum from perfusion liquid.
8, method according to claim 1 is characterized in that the isolated cells evaluation comprises the biological characteristics evaluation and multidirectional differentiation potential is identified.
9, method according to claim 8, the biological characteristics evaluation that it is characterized in that isolated cells comprises cell growth characteristic and the evaluation of morphology characteristics, flow cytometry identification of M SC surface marker, the analysis of placenta MSC cell cycle, the drafting of placenta MSC growth curve and the mensuration of logarithmic phase doubling time.
10, method according to claim 8, the multidirectional differentiation potential that it is characterized in that isolated cells identify comprise into that fat is induced, osteogenic induction with become chondrocyte induction.
CNA031235042A2003-05-092003-05-09 A method for isolating human placental mesenchymal stem cellsPendingCN1548529A (en)

Priority Applications (1)

Application NumberPriority DateFiling DateTitle
CNA031235042ACN1548529A (en)2003-05-092003-05-09 A method for isolating human placental mesenchymal stem cells

Applications Claiming Priority (1)

Application NumberPriority DateFiling DateTitle
CNA031235042ACN1548529A (en)2003-05-092003-05-09 A method for isolating human placental mesenchymal stem cells

Publications (1)

Publication NumberPublication Date
CN1548529Atrue CN1548529A (en)2004-11-24

Family

ID=34321346

Family Applications (1)

Application NumberTitlePriority DateFiling Date
CNA031235042APendingCN1548529A (en)2003-05-092003-05-09 A method for isolating human placental mesenchymal stem cells

Country Status (1)

CountryLink
CN (1)CN1548529A (en)

Cited By (36)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
CN100344757C (en)*2005-10-182007-10-24天津昂赛细胞基因工程有限公司Human placenta, umbilical cord mesenchyma stemcell stock and its construction method
US7311904B2 (en)2001-02-142007-12-25Anthrogenesis CorporationTissue matrices comprising placental stem cells, and methods of making the same
US7311905B2 (en)2002-02-132007-12-25Anthrogenesis CorporationEmbryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
CN100404668C (en)*2005-09-232008-07-23中国科学院动物研究所 A kind of human placental trophoblast cell line and its application
US7468276B2 (en)2000-12-062008-12-23Anthrogenesis CorporationPlacental stem cells
US7682803B2 (en)2005-10-132010-03-23Anthrogenesis CorporationImmunomodulation using placental stem cells
US7700090B2 (en)2002-02-132010-04-20Anthrogenesis CorporationCo-culture of placental stem cells and stem cells from a second source
US7976836B2 (en)2000-12-062011-07-12Anthrogenesis CorporationTreatment of stroke using placental stem cells
CN101161249B (en)*2006-10-122011-07-20周胜利Method for extracting original mesenchyma and hematopoiesis trunks/ancestral cell from caesarean birth placenta
US7993918B2 (en)2006-08-042011-08-09Anthrogenesis CorporationTumor suppression using placental stem cells
US8057788B2 (en)2000-12-062011-11-15Anthrogenesis CorporationPlacental stem cell populations
CN102433301A (en)*2011-12-022012-05-02上海安集协康生物技术有限公司Method for extracting and amplifying monoclonal mesenchymal stem cells and culture solution for same
US8263065B2 (en)2007-09-282012-09-11Anthrogenesis CorporationTumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
US8367409B2 (en)2008-11-192013-02-05Anthrogenesis CorporationAmnion derived adherent cells
US8460650B2 (en)2007-02-122013-06-11Anthrogenesis CorporationTreatment of inflammatory diseases using placental stem cells
US8562973B2 (en)2010-04-082013-10-22Anthrogenesis CorporationTreatment of sarcoidosis using placental stem cells
US8673547B2 (en)2007-03-082014-03-18Hemacell Perfusion, Inc.Method for isolation of afterbirth derived cells
US8728805B2 (en)2008-08-222014-05-20Anthrogenesis CorporationMethods and compositions for treatment of bone defects with placental cell populations
US8828376B2 (en)2008-08-202014-09-09Anthrogenesis CorporationTreatment of stroke using isolated placental cells
US8926964B2 (en)2010-07-132015-01-06Anthrogenesis CorporationMethods of generating natural killer cells
US8969315B2 (en)2010-12-312015-03-03Anthrogenesis CorporationEnhancement of placental stem cell potency using modulatory RNA molecules
US9040035B2 (en)2011-06-012015-05-26Anthrogenesis CorporationTreatment of pain using placental stem cells
CN104726401A (en)*2015-02-132015-06-24中国医科大学Method for improving success rate of umbilical cord blood mesenchymal stem cell culture by using placental mesenchymal stem cells
US9121007B2 (en)2010-01-262015-09-01Anthrogenesis CorporatinTreatment of bone-related cancers using placental stem cells
US9254302B2 (en)2010-04-072016-02-09Anthrogenesis CorporationAngiogenesis using placental stem cells
CN105420181A (en)*2015-12-092016-03-23南方医科大学南方医院Method for separating in-vitro mesenchymal cells
US9364585B2 (en)2006-05-112016-06-14Anthrogenesis CorporationMethods for collecting and using placenta cord blood stem cells
CN106544318A (en)*2016-11-282017-03-29广东万海细胞生物科技有限公司Promote umbilical cord mesenchymal stem cells directed differentiation for the method for adipose cell
CN107028981A (en)*2007-09-192017-08-11普拉里斯坦有限公司Adherent cell from fat or placenta tissue and its purposes in the treatment
US9763983B2 (en)2013-02-052017-09-19Anthrogenesis CorporationNatural killer cells from placenta
CN107858326A (en)*2017-12-122018-03-30上海银海圣生物科技有限公司Murine preadipocyte cell 3T3 L1 differentiation-inducing agents and method of inducing differentiation
US9944900B2 (en)2006-01-182018-04-17Hemacell PerfusionPulsatile perfusion extraction method for non-embryonic pluripotent stem cells
US10104880B2 (en)2008-08-202018-10-23Celularity, Inc.Cell composition and methods of making the same
US10494607B2 (en)2007-02-122019-12-03Celularity, Inc.CD34+,CD45−placental stem cell-enriched cell populations
CN114752688A (en)*2022-04-282022-07-15北京大学口腔医学院Method, probe and kit for identifying human embryonic bone marrow-derived mesenchymal stem cells and application thereof
CN116144583A (en)*2023-04-192023-05-23北京雪颜博润生物科技有限公司Method for obtaining human placenta embryo-derived stem cells and application

Cited By (61)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US7976836B2 (en)2000-12-062011-07-12Anthrogenesis CorporationTreatment of stroke using placental stem cells
US8580563B2 (en)2000-12-062013-11-12Anthrogenesis CorporationPlacental stem cells
US8057788B2 (en)2000-12-062011-11-15Anthrogenesis CorporationPlacental stem cell populations
US9149569B2 (en)2000-12-062015-10-06Anthrogenesis CorporationTreatment of diseases or disorders using placental stem cells
US7468276B2 (en)2000-12-062008-12-23Anthrogenesis CorporationPlacental stem cells
US8545833B2 (en)2000-12-062013-10-01Anthrogenesis CorporationTreatment of radiation injury using placental stem cells
US8293223B2 (en)2000-12-062012-10-23Anthrogenesis CorporationTreatment of organ injuries and burns using placental stem cells
US7311904B2 (en)2001-02-142007-12-25Anthrogenesis CorporationTissue matrices comprising placental stem cells, and methods of making the same
US7914779B2 (en)2001-02-142011-03-29Anthrogenesis CorporationTissue matrices comprising placental stem cells, and methods of making the same
US9139813B2 (en)2001-02-142015-09-22Anthrogenesis CorporationRenovation and repopulation of decellularized tissues and cadaveric organs by stem cells
US8435788B2 (en)2001-02-142013-05-07Anthrogenesis CorporationTissue matrices comprising placental stem cells
US7700090B2 (en)2002-02-132010-04-20Anthrogenesis CorporationCo-culture of placental stem cells and stem cells from a second source
US8057789B2 (en)2002-02-132011-11-15Anthrogenesis CorporationPlacental stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
US7311905B2 (en)2002-02-132007-12-25Anthrogenesis CorporationEmbryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
US8753883B2 (en)2002-02-132014-06-17Anthrogenesis CorporationTreatment of psoriasis using placental stem cells
CN100404668C (en)*2005-09-232008-07-23中国科学院动物研究所 A kind of human placental trophoblast cell line and its application
US7682803B2 (en)2005-10-132010-03-23Anthrogenesis CorporationImmunomodulation using placental stem cells
US8895256B2 (en)2005-10-132014-11-25Anthrogenesis CorporationImmunomodulation using placental stem cells
US8216566B2 (en)2005-10-132012-07-10Anthrogenesis CorporationTreatment of multiple sclerosis using placental stem cells
US9539288B2 (en)2005-10-132017-01-10Anthrogenesis CorporationImmunomodulation using placental stem cells
CN100344757C (en)*2005-10-182007-10-24天津昂赛细胞基因工程有限公司Human placenta, umbilical cord mesenchyma stemcell stock and its construction method
US8202703B2 (en)2005-12-292012-06-19Anthrogenesis CorporationPlacental stem cell populations
US10383897B2 (en)2005-12-292019-08-20Celularity, Inc.Placental stem cell populations
US9078898B2 (en)2005-12-292015-07-14Anthrogenesis CorporationPlacental stem cell populations
US8455250B2 (en)2005-12-292013-06-04Anthrogenesis CorporationCo-culture of placental stem cells and stem cells from a second source
US8591883B2 (en)2005-12-292013-11-26Anthrogenesis CorporationPlacental stem cell populations
US8691217B2 (en)2005-12-292014-04-08Anthrogenesis CorporationPlacental stem cell populations
US9944900B2 (en)2006-01-182018-04-17Hemacell PerfusionPulsatile perfusion extraction method for non-embryonic pluripotent stem cells
US9364585B2 (en)2006-05-112016-06-14Anthrogenesis CorporationMethods for collecting and using placenta cord blood stem cells
US7993918B2 (en)2006-08-042011-08-09Anthrogenesis CorporationTumor suppression using placental stem cells
CN101161249B (en)*2006-10-122011-07-20周胜利Method for extracting original mesenchyma and hematopoiesis trunks/ancestral cell from caesarean birth placenta
US10494607B2 (en)2007-02-122019-12-03Celularity, Inc.CD34+,CD45−placental stem cell-enriched cell populations
US8460650B2 (en)2007-02-122013-06-11Anthrogenesis CorporationTreatment of inflammatory diseases using placental stem cells
US8916146B2 (en)2007-02-122014-12-23Anthrogenesis CorporationTreatment of inflammatory diseases using placental stem cells
US8673547B2 (en)2007-03-082014-03-18Hemacell Perfusion, Inc.Method for isolation of afterbirth derived cells
CN107028981A (en)*2007-09-192017-08-11普拉里斯坦有限公司Adherent cell from fat or placenta tissue and its purposes in the treatment
CN107028981B (en)*2007-09-192021-04-20普拉里斯坦有限公司Adherent cells from adipose or placental tissue and their use in therapy
US9216200B2 (en)2007-09-282015-12-22Anthrogenesis CorporationTumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
US8263065B2 (en)2007-09-282012-09-11Anthrogenesis CorporationTumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
US10104880B2 (en)2008-08-202018-10-23Celularity, Inc.Cell composition and methods of making the same
US8828376B2 (en)2008-08-202014-09-09Anthrogenesis CorporationTreatment of stroke using isolated placental cells
US8728805B2 (en)2008-08-222014-05-20Anthrogenesis CorporationMethods and compositions for treatment of bone defects with placental cell populations
US9198938B2 (en)2008-11-192015-12-01Antrhogenesis CorporationAmnion derived adherent cells
US8367409B2 (en)2008-11-192013-02-05Anthrogenesis CorporationAmnion derived adherent cells
US9121007B2 (en)2010-01-262015-09-01Anthrogenesis CorporatinTreatment of bone-related cancers using placental stem cells
US9254302B2 (en)2010-04-072016-02-09Anthrogenesis CorporationAngiogenesis using placental stem cells
US8562973B2 (en)2010-04-082013-10-22Anthrogenesis CorporationTreatment of sarcoidosis using placental stem cells
US8926964B2 (en)2010-07-132015-01-06Anthrogenesis CorporationMethods of generating natural killer cells
US9464274B2 (en)2010-07-132016-10-11Anthrogenesis CorporationMethods of generating natural killer cells
US8969315B2 (en)2010-12-312015-03-03Anthrogenesis CorporationEnhancement of placental stem cell potency using modulatory RNA molecules
US11090339B2 (en)2011-06-012021-08-17Celularity Inc.Treatment of pain using placental stem cells
US9040035B2 (en)2011-06-012015-05-26Anthrogenesis CorporationTreatment of pain using placental stem cells
CN102433301A (en)*2011-12-022012-05-02上海安集协康生物技术有限公司Method for extracting and amplifying monoclonal mesenchymal stem cells and culture solution for same
US9763983B2 (en)2013-02-052017-09-19Anthrogenesis CorporationNatural killer cells from placenta
CN104726401A (en)*2015-02-132015-06-24中国医科大学Method for improving success rate of umbilical cord blood mesenchymal stem cell culture by using placental mesenchymal stem cells
CN105420181A (en)*2015-12-092016-03-23南方医科大学南方医院Method for separating in-vitro mesenchymal cells
CN106544318A (en)*2016-11-282017-03-29广东万海细胞生物科技有限公司Promote umbilical cord mesenchymal stem cells directed differentiation for the method for adipose cell
CN107858326A (en)*2017-12-122018-03-30上海银海圣生物科技有限公司Murine preadipocyte cell 3T3 L1 differentiation-inducing agents and method of inducing differentiation
CN114752688A (en)*2022-04-282022-07-15北京大学口腔医学院Method, probe and kit for identifying human embryonic bone marrow-derived mesenchymal stem cells and application thereof
CN114752688B (en)*2022-04-282024-02-23北京大学口腔医学院Method, probe and kit for identifying mesenchymal stem cells derived from human embryo bone marrow and application thereof
CN116144583A (en)*2023-04-192023-05-23北京雪颜博润生物科技有限公司Method for obtaining human placenta embryo-derived stem cells and application

Similar Documents

PublicationPublication DateTitle
CN1548529A (en) A method for isolating human placental mesenchymal stem cells
Mennan et al.A comprehensive characterisation of large-scale expanded human bone marrow and umbilical cord mesenchymal stem cells
Pal et al.Phenotypic and functional comparison of optimum culture conditions for upscaling of bone marrow‐derived mesenchymal stem cells
CN102676451B (en)Method for separating mesenchymal stem cells from placenta
Zhu et al.Manual isolation of adipose-derived stem cells from human lipoaspirates
Chong et al.Human peripheral blood derived mesenchymal stem cells demonstrate similar characteristics and chondrogenic differentiation potential to bone marrow derived mesenchymal stem cells
CN102586184B (en)Method for establishing placental mesenchyme stem cell library
CN103805562B (en)Cultivate the serum free medium of placenta mesenchyma stem cell
Stoltz et al.Mesenchymal stem cells derived from Wharton's jelly: comparative phenotype analysis between tissue and in vitro expansion
CN102807966B (en)Method for freezing and thawing placental whole cells and separating and expanding stem cells
CN102660497B (en)Method for freezing and reviving umbilical cord tissues and for separating and increasing stem cells
CN104164403B (en)Method for extracting and culturing adipose-derived stem cells
Froelich et al.Chromosomal aberrations and deoxyribonucleic acid single-strand breaks in adipose-derived stem cells during long-term expansion in vitro
CN101629165B (en)Preparation method of original mesenchymal stem cell
CN102367435B (en)Preparation of human platelet-rich plasma and application of same in isolation and culture of human mesenchymal stem cells
CN109234229B (en)Method for separating mesenchymal stem cells from placental blood vessels and digestive enzyme composition used in same
CN102660501A (en)Method for separating and amplifying mesenchymal stem cell from fresh tissue of umbilical cord
CN102433301A (en)Method for extracting and amplifying monoclonal mesenchymal stem cells and culture solution for same
CN108300690A (en)A kind of isolated culture method and serum free medium of fat mesenchymal stem cell
CN102660503A (en)Method for separating and amplifying mesenchymal stem cells from umbilical cord
CN109628388B (en)Isolation of mesenchymal stem cells from placental blood vessels with digestive enzyme composition
CN108220230A (en)A kind of separation of human adipose-derived stem cell and cultural method
Narakornsak et al.Mesenchymal stem cells differentiated into chondrocyte—Like cells
CN102533643A (en)Method for isolation and serum gradient switching culture of human umbilical cord mesenchymal stem cells
CN101948804A (en)Preparation method of umbilical cord mesenchymal stem cells

Legal Events

DateCodeTitleDescription
C06Publication
PB01Publication
C10Entry into substantive examination
SE01Entry into force of request for substantive examination
C02Deemed withdrawal of patent application after publication (patent law 2001)
WD01Invention patent application deemed withdrawn after publication

[8]ページ先頭

©2009-2025 Movatter.jp